ArticleJournal of diabetes investigation2026
Serum-derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesWe aimed to identify microribonucleic acids (miRNAs) that could serve as biomarkers for slowly progressive type 1 diabetes mellitus (SPIDDM). MATERIALS AND
methodsWe conducted a retrospective study of adult patients with SPIDDM who fulfilled the criteria for SPIDDM (definite) (n = 60), type 2 diabetes mellitus (T2DM) (n = 59), and healthy controls (n = 50) to analyze the serum expression levels of 40 miRNAs reported to be altered in latent autoimmune diabetes in adults and type 1 diabetes using quantitative real-time polymerase chain reaction, specifically analyzing serum collected at the time of diagnosis as SPIDDM (probable) in the SPIDDM group. For miRNAs showing significant differences between the groups, we performed logistic regression analysis. In the SPIDDM group, we performed linear regression analysis on miRNAs correlated with the C-peptide index (CPI) at the last outpatient visit as identified by Spearman's rank correlation.
resultsThe serum expression levels of miR-143-3p, miR-21-5p, miR-223-3p, and miR-517b-3p differed significantly in the SPIDDM group compared with the type 2 diabetes mellitus and control groups. Multivariate logistic regression analysis distinguishing SPIDDM from type 2 diabetes mellitus revealed miR-21-5p, miR-223-3p, and miR-517b-3p as independent discriminators. Correlation and multivariate linear regression analyses revealed that miR-150-5p was selected as an independent predictor of CPI at the last outpatient visit.
conclusionThis study identified serum miRNAs as potential biomarkers in adult patients with SPIDDM, particularly miR-150-5p as a candidate marker for predicting subsequent decline in insulin secretion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.